ecteinascidin 743 has been researched along with olaparib in 4 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (olaparib) | Trials (olaparib) | Recent Studies (post-2010) (olaparib) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 1,313 | 172 | 1,258 |
| Protein | Taxonomy | ecteinascidin 743 (IC50) | olaparib (IC50) |
|---|---|---|---|
| Poly [ADP-ribose] polymerase tankyrase-1 | Homo sapiens (human) | 1.538 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.02 | |
| Cholinesterase | Homo sapiens (human) | 0.0035 | |
| Poly [ADP-ribose] polymerase 1 | Homo sapiens (human) | 0.1741 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.02 | |
| Protein mono-ADP-ribosyltransferase PARP6 | Homo sapiens (human) | 1.8 | |
| Protein mono-ADP-ribosyltransferase PARP15 | Homo sapiens (human) | 7.6216 | |
| Protein mono-ADP-ribosyltransferase PARP10 | Homo sapiens (human) | 5.2854 | |
| Protein mono-ADP-ribosyltransferase PARP16 | Homo sapiens (human) | 5.1143 | |
| Poly [ADP-ribose] polymerase tankyrase-2 | Homo sapiens (human) | 2.3349 | |
| Histamine H3 receptor | Cavia porcellus (domestic guinea pig) | 0.001 | |
| Poly [ADP-ribose] polymerase 2 | Homo sapiens (human) | 0.1866 | |
| Protein mono-ADP-ribosyltransferase PARP4 | Homo sapiens (human) | 0.4087 | |
| Protein mono-ADP-ribosyltransferase PARP3 | Homo sapiens (human) | 0.1315 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alonso, D; Amaral, AT; Aracil, M; Carcaboso, AM; de Álava, E; del Carmen García-Macías, M; Fraile, S; Galmarini, CM; Herrero-Martín, D; Mayo-Iscar, A; Mora, J; Ordóñez, JL; Pascual-Pasto, G; Rodrigues, T; San-Segundo, L; Sevillano, V; Teodosio, C; Tirado, OM; Vila-Ubach, M | 1 |
| Aglietta, M; Aliberti, S; Basiricò, M; Benassi, MS; Boccone, P; Canta, M; Capozzi, F; Chiabotto, G; Chiorino, G; D'Ambrosio, L; Dell'Aglio, C; Galizia, D; Gammaitoni, L; Grignani, G; Lorenzato, A; Miano, S; Napione, L; Palesandro, E; Pasini, B; Pignochino, Y; Sangiolo, D; Vignolo Lutati, F | 1 |
| Aglietta, M; Aliberti, S; Bardelli, A; Bartolini, A; Bertulli, R; Boccone, P; Chiabotto, G; D'Ambrosio, L; D'Incalci, M; Dei Tos, AP; Ferrari, S; Grignani, G; Marchesi, E; Miano, S; Novara, L; Palmerini, E; Piana, R; Picci, P; Pignochino, Y; Pisacane, A; Sangiolo, D; Stacchiotti, S; Tolomeo, F; Zucchetti, M | 1 |
| Nacev, BA; Tap, WD | 1 |
1 trial(s) available for ecteinascidin 743 and olaparib
| Article | Year |
|---|---|
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Italy; Male; Middle Aged; Osteosarcoma; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Sarcoma; Soft Tissue Neoplasms; Time Factors; Trabectedin | 2018 |
3 other study(ies) available for ecteinascidin 743 and olaparib
| Article | Year |
|---|---|
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Child; Dioxoles; DNA Damage; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Random Allocation; Sarcoma, Ewing; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2015 |
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Comparative Genomic Hybridization; Dioxoles; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Mice; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
TOMAS: revisiting PARP inhibitor combination therapy.
Topics: Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Sarcoma; Trabectedin | 2018 |